Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prevalence and Profile of Aspirin Resistance in Hemodialysis Patients

This study has been completed.
Staten Island University Hospital
Information provided by (Responsible Party):
Suzanne El-Sayegh, North Shore Long Island Jewish Health System Identifier:
First received: November 14, 2008
Last updated: July 19, 2013
Last verified: July 2013

Dialysis patient could be more aspirin resistant than the general population based on data from chronic kidney disease patients

Aspirin Resistance

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Prevalence of Aspirin Resistance in Hemodialysis Patients

Resource links provided by NLM:

Further study details as provided by North Shore Long Island Jewish Health System:

Primary Outcome Measures:
  • Aspirin Resistance in Hemodialysis patients [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Enrollment: 100
Study Start Date: June 2008
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Detailed Description:

We will try to describe the profile of aspirin resistant patient in hemodialysis patients


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

all hemodialysis patients on aspirin


Inclusion Criteria:

  • all hemodialysis patients on aspirin

Exclusion Criteria:

  • low platelets <100.000
  • coagulopathy, bleeding disorders
  • patient on plavix
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00792272

Sponsors and Collaborators
North Shore Long Island Jewish Health System
Staten Island University Hospital
Principal Investigator: Suzanne El-Sayegh, MD SIUH
  More Information

No publications provided

Responsible Party: Suzanne El-Sayegh, Assoc. Chair of Medicine, North Shore Long Island Jewish Health System Identifier: NCT00792272     History of Changes
Other Study ID Numbers: 08-013
Study First Received: November 14, 2008
Last Updated: July 19, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by North Shore Long Island Jewish Health System:
aspirin resistance
aspirin resistance in hemodialysis patients

Additional relevant MeSH terms:
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Cardiovascular Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Sensory System Agents
Therapeutic Uses processed this record on November 23, 2014